Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
4D Molecular Therapeutics Inc
FDMT | US
8.54
USD-0.33
-3.72%
FDMT | US
About 4D Molecular Therapeutics Inc
Sector
Healthcare
Industry
Biotechnology
Earnings date
30/06/2024
As of date
11/03/2026
Close
8.54
Open
8.71
High
8.71
Low
8.34
4D Molecular Therapeutics Inc. a clinical-stage biotherapeutics company develops genetic medicines using its therapeutic vector evolution platform. It develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas: ophthalmology cardiology and pulmonology. The company has product candidates that are in clinical trials such as 4D-125 that is in a Phase 1/2 clinical trial for the treatment of X-linked retinitis pigmentosa; 4D-110 that is in a Phase 1/2 clinical trial for the treatment of choroideremia; and 4D-310 which is in a Phase 1/2 clinical trial for the treatment of Fabry disease cardiomyopathy. Its product candidates also include 4D-150 for the treatment of wet age-related macular degeneration and diabetic macular edema; and 4D-710 for the treatment of cystic fibrosis lung disease. In addition the company has two product candidates that are in preclinical development stage such as 4D-175 for the treatment of geographic atrophy; and 4D-725 for the treatment of alpha-1 antitrypsin deficiency lung disease. It has research and collaboration arrangements with uniQure; CRF; Roche; and CFF. The company was founded in 2013 and is headquartered in Emeryville California.
View LessFDMT | US
Risk
56.6
Sharpe
1.18
Luna's Score
37/100
Recommendation
Sell
Luna says (FDMT | US)
What's Working
Low Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
Value Stock (Price to Book < 3)
What's not Working
Negative Momentum (Declining Price)
Price Below SMA10D
High 6-Month Volatility (>65%)
Smallcap (300M - 2B USD)
High Market Beta (> 0.8)
High Short percentage (> 15%)
Weak Operating Margin (< 10%)
Declining Revenue (< 0%)
Volatility Signals
Bearish: Increased Volatility (6-month > 1-month volatility)
Risk Meter
10 days
62.6%1 month
56.6%3 months
80.4%6 months
84.2%Returns
Fundamental Ratios
PE
-
Fwd. PE
-
Price to book
0.75
Debt to equity
0.02
Debt to assets
0.02
Ent. to EBITDA
-3.55
Ent. to rev.
8.57
PEG
-
Other Fundamentals
EBITDA
-126.75M
MarketCap
443.82M
MarketCap(USD)
443.82M
Div. yield
-
Op. margin
-849.12K
Erngs. growth
-
Rev. growth
-97.90
Ret. on equity
-24.06
Short ratio
11.42
Short perc.
21.78
Market Sentiment (SMA and Price signals)
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bullish (SMA1M > SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
SMAs: Stock Price Trends
Range10D
2.43
Range1M
2.52
Range3M
4.85
Volumes: Market Activity
Rel. volume
0.55
Price X volume
3.46M
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | -3.55 | - | Cheaper |
| Ent. to Revenue | 8.57 | - | Cheaper |
| PE Ratio | - | 41.03 | - |
| Price to Book | 0.75 | 15.55 | Cheaper |
| Dividend Yield | - | - | - |
| Std. Deviation (3M) | 80.37 | - | Par |
| Debt to Equity | 0.02 | -1.23 | Expensive |
| Debt to Assets | 0.02 | 0.25 | Cheaper |
| Market Cap | 443.82M | - | Emerging |
